{"id":"NCT00393939","sponsor":"Pfizer","briefTitle":"Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer","officialTitle":"A Randomized Phase 3 Study Of Docetaxel In Combination With Sunitinib Versus Docetaxel In The First-Line Treatment Of Advanced Breast Cancer Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-02","primaryCompletion":"2010-02","completion":"2011-07","firstPosted":"2006-10-31","resultsPosted":"2011-02-28","lastUpdate":"2012-07-19"},"enrollment":594,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Breast Neoplasms"],"interventions":[{"type":"DRUG","name":"Sunitinib malate","otherNames":[]},{"type":"DRUG","name":"Taxotere","otherNames":[]}],"arms":[{"label":"A","type":"EXPERIMENTAL"},{"label":"B","type":"ACTIVE_COMPARATOR"}],"summary":"This is a phase 3 randomized trial evaluating the anti-tumor activity and safety of sunitinib combined with docetaxel versus docetaxel, administered as first-line treatment, in patients with unresectable locally recurrent or metastatic breast cancer.","primaryOutcome":{"measure":"Progression-Free Survival (PFS)","timeFrame":"Baseline up to Month 33","effectByArm":[{"arm":"Docetaxel + Sunitinib","deltaMin":8.6,"sd":null},{"arm":"Docetaxel","deltaMin":8.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.2651"},{"comp":"OG000 vs OG001","p":"0.0753"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":144,"countries":["United States","Argentina","Australia","Austria","Belgium","Canada","Colombia","Czechia","Finland","France","Germany","Hungary","Ireland","Italy","Netherlands","Panama","Poland","Portugal","Romania","Russia","Slovakia","South Korea","Spain","Sweden","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":[],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A6181064&StudyName=Study%20Of%20Sunitinib%20In%20Combination%20With%20Docetaxel%20Vs%20Docetaxel%20In%20Patients%20With%20Advanced%20Breast%20Cancer"]},"adverseEventsSummary":{"seriousAny":{"events":112,"n":295},"commonTop":["Alopecia","Neutropenia","Diarrhoea","Nausea","Fatigue"]}}